| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000036216 |
| Receipt No. | R000041256 |
| Scientific Title | The efficacy evaluation of the dietary supplement (composite material) on the low back pain and physical |
| Date of disclosure of the study information | 2019/03/17 |
| Last modified on | 2019/09/17 (Ver. 4) |
| Basic information | ||
| Public title | The efficacy evaluation of the dietary supplement (composite material) on the low back pain and physical | |
| Acronym | The efficacy evaluation of the dietary supplement on the low back pain | |
| Scientific Title | The efficacy evaluation of the dietary supplement (composite material) on the low back pain and physical | |
| Scientific Title:Acronym | The efficacy evaluation of the dietary supplement on the low back pain | |
| Region |
|
|
| Condition | |||
| Condition | None | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To investigate the efficacy of the dietary supplement on the low back pain and physical evaluation for 8 weeks |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | JLEQ
Low back range of motion |
| Key secondary outcomes | Trunk muscle strength
Core temperature VAS (Joint pain of knee, elbow, ankle, shoulder, neck, back and hip and finger) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of test food for 8 weeks | |
| Interventions/Control_2 | Ingestion of placebo food for 8 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1) Males and females at the ages of 20 to 60
(2) Subjects who have continuous low back pain for 3 months or more (3) Subjects who have habit of sleeping on bedding alone (4) Subjects with narrow values on low back range of motion |
|||
| Key exclusion criteria | Subjects
(1) which low back pain is weaker than pain in other joints (2) who are suspected gouty attack with hyperuricemia (3) who have positive rheumatoid factors on the screening test or may have rheumatic pain (4) who have performed arthroplasty or need it (5) who regularly take health food which may affect this study from three month before the screening test to the end of the study (6) who regularly take medicine (7) who have been performed intra-articular hyaluronic acid or steroid drug injection within a year before the screening test (8) who get an intense exercise to make excessive load on the body (9) who have a history of the disorder related to bone and joint such as fracture and sprain within a year before the screening test (10) who regularly use a cane, supporter or corset (11) who periodically conduct actions that may affect the evaluation of effectiveness (12) who have under treatment that may affect the evaluation of effectiveness (13) who have nervous system diseases or severe diseases such as, malignant tumors, diabetes, liver diseases, kidney diseases, heart diseases, etc. and have a history of serious disorder (14) who has under treatment or a history of mental diseases or is strongly suspected of mental diseases (15) who work night and day shift or who work manual labor (16) who drink alcohol in large quantities (17) who regularly smoke or who started smoking cessation one year before screening test (18) who have possibilities for emerging allergy onset related to the study (19) who are judged as unsuitable for the study based on the results of clinical and physical examination on preliminary examination (20) who have participated in other clinical study within a month before the screening test or who intend to participate in study period (21) who intend to become pregnant or lactating (22) who are judged as unsuitable due to lifestyle questionnaire (23) who are judged as unsuitable for the study by investigator for other reasons |
|||
| Target sample size | 70 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Q'SAI CO., LTD. | ||||||
| Division name | Research and Development Department | ||||||
| Zip code | 810-8606 | ||||||
| Address | 1-7-16 Kusagae, Chuo-ku, Fukuoka-shi, Japan | ||||||
| TEL | 092-724-0855 | ||||||
| ito@kyusai.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | TTC Co., Ltd. | ||||||
| Division name | Clinical Research Planning Department | ||||||
| Zip code | 150-0021 | ||||||
| Address | Seibu Shinkin Bank Ebisu Bldg.,1-20-2, Ebisunishi, Shibuya-ku, Tokyo | ||||||
| TEL | 03-5459-5329 | ||||||
| Homepage URL | |||||||
| k.isobe@ttc-tokyo.co.jp | |||||||
| Sponsor | |
| Institute | TTC Co., Ltd |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Q'SAI CO., LTD. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Aisei Hospital Ueno Clinic Reserch Ethics Committee |
| Address | 2-18-6 Higashiueno, Taito-ku, Tokyo, Japan |
| Tel | 03-6455-0880 |
| t.saito@ttc-smo.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041256 |